Skip to content

Insider · CIK 0001831410

Cyrus Harmon

director

Files at OLMA (Olema Pharmaceuticals, Inc.). First filing Dec 11, 2024, latest Dec 11, 2024.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $148k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

OLMA: Olema Pharmaceuticals, Inc.

OLMAOct 9, 2026 · close 7.82

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
41Moderate
OLMAsell 6
Olema Pharmaceuticals, Inc.
$148k
16,393 shares
-2%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Dec 9, 2024OLMA
Olema Pharmaceuticals, Inc.
AGrant or award
Common Stock
+29,250$0.00$0780,533Dec 11, 2024
Dec 10, 2024OLMA
Olema Pharmaceuticals, Inc.
SOpen-market sale
Common Stock
-8,256$9.37$77k772,277Dec 11, 2024
Dec 11, 2024OLMA
Olema Pharmaceuticals, Inc.
SOpen-market sale
Common Stock
-7,958$8.66$69k764,319Dec 11, 2024
Dec 11, 2024OLMA
Olema Pharmaceuticals, Inc.
SOpen-market sale
Common Stock
-179$9.39$1,681764,140Dec 11, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Cyrus Harmon: insider trades and track record | InsiderTell